BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, November 21, 2024
Breaking News: Healing a health divide (that’s long overdue)
See today's BioWorld Science
Home
» Imidazopyrimidine TLR7/8 agonist adjuvant formulation with enhanced Th-polarizing immunity
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full article
sign up for free
or
sign in
.
Immune
Imidazopyrimidine TLR7/8 agonist adjuvant formulation with enhanced Th-polarizing immunity
July 17, 2024
No Comments
Researchers from Children’s Hospital Boston and affiliated organizations have reported the discovery and preclinical characterization of a novel TLR7/8 agonist adjuvant for vaccination, PVP-037.
BioWorld Science
Immune
Infection
Coronavirus
